Raymond Pratt

This inventor holds 5 USPTO granted patents and 2 published patent applications and 1 EPO patent. Top assignee: Eisai Company, Limited. Active years: 2002-2009.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Raymond Pratt. Retrieved from https://idiyas.com/inventor/raymond-pratt

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 5 (Patent Applications = 2)

% Patents Active = 20.0

EPO Patents = 1 (Patent Applications = 3)

Average Co-Inventor Count = 1.0

ph-index = 5

Forward Citations = 137(Granted Patents)

Company Filing History:

5 out of 677

Eisai Company, Limited

patents

Years Active: 2002-2009

Loading Chart...

5 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7563808 - Methods for treating cognitive impairments or dementia (2009-07-21),

2. 6689795 - Methods for treating dementia due to HIV disease (2004-02-10),

3. 6576646 - Methods for treating cognitive impairments caused by traumatic brain injuries (2003-06-10),

4. 6482838 - Methods for treating cognitive impairments caused by traumatic brain injuries (2002-11-19),

5. 6458807 - Methods for treating vascular dementia (2002-10-01),

Title: Innovations by Raymond Pratt in Cognitive Health

Introduction

Raymond Pratt is an accomplished inventor based in Leonia, NJ (US). He has made significant contributions to the field of cognitive health, holding a total of 5 patents. His work focuses on innovative methods for treating various cognitive impairments and dementia-related conditions.

Latest Patents

Pratt's latest patents include groundbreaking methods for treating cognitive impairments or dementia. These inventions describe novel approaches to prevent and treat dementia caused by vascular diseases, Parkinson's disease, Lewy Body dementia, and AIDS dementia, among others. The methods also address cognitive impairments associated with neurologic and psychiatric conditions, such as epilepsy and schizophrenia. Additionally, his patents outline treatments for conditions like Tourette's syndrome, attention deficit hyperactivity disorder, and even sleep apnea. A preferred cholinesterase inhibitor for use in these methods is donepezil hydrochloride, commonly known as ARICEPT®.

Career Highlights

Raymond Pratt is affiliated with Eisai Company, Limited, where he continues to develop and refine his innovative approaches to cognitive health. His work has the potential to significantly impact the treatment of various cognitive disorders, improving the quality of life for many individuals.

Conclusion

Raymond Pratt's contributions to cognitive health through his innovative patents demonstrate his commitment to advancing medical science. His work not only addresses pressing health issues but also paves the way for future research and development in the field.

Profile summary based on public USPTO records.